Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

COVAX vaccine supply outstrips demand for the first time

Wed, 23rd Feb 2022 06:00

BRUSSELS/LONDON, Feb 23 (Reuters) - The global project to share COVID-19 vaccines is struggling to place more than 300 million doses in the latest sign the problem with vaccinating the world is now more about demand than supply.

Last year, wealthy nations snapped most of the available shots to inoculate their own citizens first, meaning less than a third of people in low-income countries have been vaccinated so far compared with more than 70% in richer nations.

As supply and donations have ramped up, however, poorer nations are facing hurdles such as gaps in cold-chain shortage, vaccine hesitancy and a lack of money to support distribution networks, public health officials told Reuters.

In January, COVAX, the global vaccine programme run by Gavi and the World Health Organization (WHO), had 436 million vaccines to allocate to countries, according to a document published in mid-February.

But low-income nations only asked for 100 million doses for distribution by the end of May - the first time in 14 allocation rounds that supply has outstripped demand, the document from the COVAX Independent Allocation of Vaccines Group said.

Asked to comment, a Gavi spokesperson said COVAX was now in a situation where there was enough current supply to meet demand, but acknowledged that the roll-out of vaccines was an issue in several less developed nations.

"We will only close the vaccine equity gap once and for all if we are able to help countries roll out vaccines rapidly and at scale," the spokesperson said.

Vaccines that are not assigned by COVAX in this round can be allocated again later.

While wealthy countries are opening up their economies, the WHO and other public health experts warn that the slow roll-out of vaccines in poorer regions will give the coronavirus a chance to mutate again and potentially create new variants.

FRIDGES AND FREEZERS

The low demand for vaccines in the January allocation is partly explained by recent increases in supplies. COVAX has already assigned tens of millions of doses to be delivered in the first quarter and delivered its billionth dose in January.

Officials involved in vaccine distribution said that meant countries were reluctant to take on more doses that they would not be able to use.

A summit to address distribution challenges is taking place on Wednesday in Abuja, Nigeria, convened by the African Union's Africa Vaccine Delivery Alliance with WHO, Gavi and others rolling out shots across Africa attending.

There had been hopes that African countries would be able to administer billions of doses of COVID-19 vaccines given their experience in dealing with deadly diseases from Ebola to malaria.

But two years into the crisis, a survey seen by Reuters by the United Nations Children's Fund (UNICEF) in January on the equipment needed to ramp up vaccine distribution highlighted some of the challenges.

It found "critical gaps" across 44 of the African Union's 55 member states: 24 countries said they needed fridges, 18 were in need of deep freezers, 22 required walk-in freezers and 16 did not have sufficient walk-in cold rooms.

A UNICEF spokesperson said more than 800 ultra-cold chain freezers had already been delivered to nearly 70 countries, as well as 52,000 fridges.

"We are continuing to help countries identify and close cold chain capacity gaps as supply increases and governments adjust national-level vaccination targets in response," she said.

DISINFORMATION AND FUNDING

The problem is particularly acute for COVAX because the Pfizer-BioNTech shot that needs to be kept super-cold has replaced AstraZeneca's vaccine as the main one being offered by the global programme.

Some African countries, such as Burundi and Guinea, have gaps at every point in the cold chain, from national level to local distribution centres, the UNICEF survey showed.

The findings are likely to underscore growing concerns that COVAX did not invest quickly enough in infrastructure and equipment for countries it was delivering vaccines to.

The issue is exacerbated by a lack of funding and because countries have not had enough notice of deliveries - particularly donations - making it harder for them to plan vaccination campaigns, public health officials have said.

Officials involved in the distribution of vaccines in Africa also said more focus needed to be placed on communicating the importance of getting vaccinated - and addressing disinformation.

"Communication is one of the biggest issues ... if we don't get the messaging right, everything else we are doing is futile," one of the officials said, speaking on condition of anonymity.

Money has also started to dry up for global initiatives as richer nations seek to move on from COVID.

Gavi says it has only raised $195 million out of the $5.2 billion it has asked for this quarter. The money is used to procure and ship vaccines, as well as provide syringes and delivery support in countries. (Reporting by Jennifer Rigby and Francesco Guarascio; Editing by Josephine Mason and David Clarke)

More News
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.